This is another study showing how semaglutide improve cardiovasculat outcomes independent of weight loss.
https://www.jacc.org/doi/10.1016/j.jacbts.2026.101554
AI summary
Overview & Objective While glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide (SEMA) improve cardiovascular outcomes and symptoms in obesity-related heart failure with preserved ejection fraction (HFpEF), their precise underlying mechanisms remain incompletely understood.
This study aimed to:
Determine whether SEMA can reverse established features of obesity-induced cardiometabolic heart disease using noninvasive multiparametric cardiac magnetic resonance (CMR) imaging in mice.
Investigate whether SEMA’s cardioprotective benefits are direct or driven purely by reduced dietary intake, using a pair-fed (PF) control group .
Experimental Model & Design
Animal Model: Male C57BL/6J mice were fed a high-fat, high-sucrose (HFHS) diet for 18 weeks to establish obesity, glucose intolerance, ectopic lipid accumulation, coronary microvascular dysfunction (CMD), strain impairments, diastolic dysfunction, and interstitial fibrosis. Standard diet (SD) mice served as healthy controls.
Treatment Intervention: Mice were randomized into three HFHS treatment arms for 4 weeks:
HFHS Control: Vehicle treatment with continued HFHS diet.
HFHS + SEMA: Daily subcutaneous injections of SEMA (9 nmol/kg/day).
HFHS + PF (Pair-Fed): Food intake restricted daily to match the average consumption of SEMA-treated mice.
Imaging & Evaluation: Multiparametric CMR was performed pretreatment (18 weeks post-diet) and post-treatment (23 weeks post-diet). After 24 weeks, histological analyses were performed for interstitial fibrosis. An independent cohort underwent a 5-day treatment protocol to assess early epicardial adipose tissue (EAT) volume and fatty acid composition (FAC).
Key Findings 1. Weight Loss and Metabolic Function
Both PF and SEMA-treated mice showed weight loss and improved glucose tolerance (GTT-AUC) compared to HFHS controls.
However, SEMA-treated mice achieved significantly greater weight loss and greater improvements in glucose tolerance than pair-fed controls at 23 weeks, as food intake in PF mice rebounded after initial caloric restriction while SEMA mice maintained sustained weight loss.
2. EAT Composition and Ectopic Lipid Reduction
Short-term (5-Day Treatment): Both SEMA and PF reduced EAT volume index similarly. However, only SEMA significantly reduced the EAT saturated fatty acid index (SFAi) —a biomarker of proinflammatory fat—showing early anti-inflammatory modulation independent of volume reduction.
Long-term (4-Week Treatment): SEMA significantly reduced both EAT volume index and myocardial proton density fat fraction (PDFF) . The pair-fed group did not show significant reductions in EAT volume or myocardial fat at 4 weeks.
3. Coronary Microvascular Function
SEMA treatment significantly improved adenosine-induced stress myocardial blood flow (MBF) and reversed impaired myocardial perfusion reserve (MPR) .
Pair-fed controls showed no significant improvement in stress MBF or MPR, indicating that SEMA reverses CMD independently of reduced food intake.
4. Myocardial Structure, Function, and Fibrosis
Left Ventricular Mass: SEMA prevented progressive LV hypertrophy, whereas LV mass continued to increase in untreated HFHS and PF groups.
Cardiac Strain & Diastolic Function: SEMA reversed subclinical impairments in end-systolic circumferential strain ($E_{cc}$) and improved peak early diastolic strain rate (PEDSR) . PF controls showed no significant improvements in strain or diastolic function.
Fibrosis: Histological analysis (Picrosirius Red staining) showed that SEMA-treated mice had significantly lower levels of interstitial myocardial fibrosis compared to HFHS controls, bringing fibrosis levels down to baseline standard-diet levels.
Conclusions & Clinical Implications
Direct Cardioprotection: SEMA directly reverses key pathological hallmarks of cardiometabolic heart disease—including microvascular dysfunction, ectopic fat accumulation, myocardial strain deficits, diastolic dysfunction, and interstitial fibrosis.
Dietary Independence: Because pair-feeding failed to reproduce these cardiac improvements, the study proves that SEMA’s cardioprotective benefits occur largely independently of reduced dietary intake .
Mechanistic Insight: The findings support a framework where SEMA acts on adipose tissue to reduce proinflammatory ectopic fat deposition and local inflammation, thereby restoring microvascular function and preventing adverse cardiac remodeling.
Other Studies Showing Weight-Independent Cardioprotection Several human trials and translational studies demonstrate that GLP-1 receptor agonists (like semaglutide) offer cardiovascular benefits distinct from weight loss alone:
The SELECT Trial Sub-Analyses (2024–2025): In a prespecified analysis of the landmark SELECT trial (17,604 participants without diabetes), researchers showed that semaglutide reduced major adverse cardiovascular events (MACE) by 20% regardless of baseline weight/BMI or the amount of weight lost during the study. Statistical mediation analyses revealed that weight loss accounted for only a small portion of MACE reduction, pointing to direct mechanisms like reduced system-wide inflammation, vascular health improvement, and anti-atherosclerotic effects.
STEP-HFpEF Program: In patients with obesity-related heart failure with preserved ejection fraction (HFpEF), semaglutide rapidly improved symptoms, physical function, and biomarkers (like NT-proBNP and CRP). Secondary analyses demonstrated that these clinical improvements were only partially mediated by weight loss, with early-onset benefits occurring prior to maximal weight reduction.
SUSTAIN-6 & PIONEER 6: Earlier cardiovascular outcome trials (CVOTs) in type 2 diabetes established early reduction in MACE risk (particularly stroke and vascular events), where cardiovascular benefit curves diverged rapidly—far faster than would be expected from gradual weight loss alone.
Strengths and Weaknesses of this study Strengths
Rigorous Pair-Fed (PF) Control Group: Including a calorie-restricted, pair-fed group was crucial. It directly isolated the pharmacological effects of semaglutide from the downstream physiological effects of reduced dietary intake.
Comprehensive Multiparametric Imaging: Utilizing advanced translational CMR allowed the researchers to evaluate multiple precise biomarkers noninvasively at baseline and post-treatment—including myocardial fat (PDFF), microvascular perfusion (MPR), myocardial strain, and epicardial fat volume (EAT).
Reversal, Not Just Prevention: The study initiated treatment after cardiometabolic disease, diastolic dysfunction, and coronary microvascular dysfunction were already established, demonstrating actual therapeutic reversal rather than mere disease prevention.
Adipose Quality Assessment: Demonstrating that semaglutide uniquely altered early epicardial fat composition (reducing the saturated fatty acid index, SFAi) provided insight into anti-inflammatory actions local to the myocardium.
Weaknesses / Limitations
Preclinical Animal Model: The findings were established in male C57BL/6J mice. While mouse HFHS models reproduce key features of human HFpEF, rodent physiology differs in GLP-1 receptor distribution, metabolic rate, and drug clearance compared to humans.
Male-Only Cohort: Male mice were evaluated. Given that obesity-related HFpEF is disproportionately prevalent in postmenopausal women, excluding female mice limits the generalizability of these findings across biological sexes.
Short Treatment Duration: The treatment period lasted 4 weeks (with an early 5-day cohort). While sufficient for observing acute remodeling in mice, it leaves long-term durability and potential off-target chronic toxicity unassessed.
Pair-Fed Rebound Dynamics: Food restriction in the pair-fed group was difficult to sustain over time due to metabolic adaptation/rebound. This resulted in SEMA mice losing significantly more weight than PF controls by week 23, somewhat confounding the total weight match at the terminal timepoint despite similar early restriction.
1 Like
Re - ectopic lipid accumulation, empagliflozin attenuates it too:
SGLT2 inhibition by empagliflozin attenuates ectopic fat accumulation and improves cardiac index in parallel to ketone bodies production: the EMPAFAT study
1 Like